As Fiat Chrysler Automobiles N.V. has a P/S, P/E and P/B estimations of 0.2, 7.84 and 1.11 separately.
Synergy Pharmaceuticals, Inc.'s insider ownership stands at 0.2 percent, while its insider transaction is -3.04 percent. 20 funds opened positions while 59 raised stakes. 158.68 million shares or 6.77% more from 148.62 million shares in 2017Q1 were reported.
Williams Jones & Associates Ltd Co owns 11,000 shares. Whereas 0 of them predict the stock is a hold. Vanguard Group Inc. boosted its holdings in shares of Synergy Pharmaceuticals by 18.8% during the 1st quarter. Oppenheimer & Incorporated accumulated 95,290 shares. The third largest holder is Blackrock Inc., which now holds $58.91 million worth of this stock and that ownership represents almost 9.63% of its market capitalization. Cantor Fitzgerald maintained Synergy Pharmaceuticals Inc (NASDAQ:SGYP) rating on Wednesday, August 9. Credit Suisse Ag owns 402,894 shares.
Investors may also want to take a longer-term look at company shares. Janney Montgomery Scott Lc holds 35,500 shares.
Synergy Pharmaceuticals, Inc. (SGYP) has an Analysts' Mean Recommendation of 2. Finally, ValuEngine lowered shares of Synergy Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Friday, September 1st.
Annual Sales Growth in the past 5 years was 0 percent. Shares for $19,967 were bought by JACOB GARY S.
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) has grabbed attention from the analysts when it experienced a change of 0.00% in the current trading session to trade at $3.02. But in several cases high influential ownership could give a false signal to value investors, and can't be reconciled with the original intent of the strategy. The 1-year low was reported on Nov, 13 by Barchart.com. Stock's distance from 52 week High is -61.96% and the distance from 52 week Low is 6.25%. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 63,035 shares traded. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since November 13, 2016 and is uptrending.
TRADEMARK VIOLATION NOTICE: "Synergy Pharmaceuticals, Inc".
ConocoPhillips (NYSE:COP) posting a -1.01% after which it closed the day' session at $52.99 and the company has experienced volume of 5,502,139 shares while on average the company has a capacity of trading 6.01M share while its relative trading volume is 0.92. STATE STREET CORP also announced increased position in Synergy Pharmaceuticals Inc. Three research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company's stock. Therefore 88% are positive. Synergy Pharmaceuticals had 31 analyst reports since August 25, 2015 according to SRatingsIntel. Roth Capital reinitiated the stock with " rating in Thursday, October 29 report. JPMorgan Chase & Co. now owns 3,405,377 shares of the biopharmaceutical company's stock worth $8,820,000 after buying an additional 1,417,177 shares during the period. The mean rating score for this stock is at 1.60. The firm earned "Buy" rating on Tuesday, August 25 by BTIG Research. OxFORD Asset Management LLP now owns 2,040,297 shares of the biopharmaceutical company's stock worth $5,784,000 after buying an additional 608,402 shares in the last quarter. Synergy Pharmaceuticals presently has an average rating of Hold and an average target price of $8.39. INC. on 09/16/2016, and was a disposition of 1.97 million shares with a final price of $5.61. H.C. Wainwright has "Buy" rating and $20 target. The original version of this article can be read at investing/synergy-pharmaceuticals-sgyp-buy-rating-reiterated-at-rodman-renshaw-2/1118040.html.
According to data from Finviz's Research, The price target set for the stock is $7.90 and this sets up an interesting set of potential movement for the stock. The quarterly performance for the stock is 18.97%, while the half-yearly performance is 11.70%.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) gross margin percentage stands at 7.6% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent.
Synergy Pharmaceuticals Inc.is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies.
The stock has a market cap of $356.38M and the number of outstanding shares has been calculated 118.01M. The Company's divisions include United Kingdom, France and Ireland.